An overview on biological mechanisms of PPARs

Pharmacological Research

51, 85-94

DOI: 10.1016/j.phrs.2004.07.012

Citation Report

#	Article	IF	Citations
1	The peroxisome proliferator-activated receptor Î± activator, Wy14,643, is anti-inflammatory in vivo. Inflammopharmacology, 2005, 12, 493-504.	3.9	13
2	Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovascular Diabetology, 2005, 4, 14.	6.8	209
3	Gene-nutrient interactions during fetal development. Reproduction, 2005, 130, 401-410.	2.6	51
4	From cellular receptors to transductionâ€“transcription pathways for cytokines: at which level should the inhibition be targeted in inflammation?. Expert Opinion on Biological Therapy, 2005, 5, S83-S96.	3.1	8
5	Fenofibrate, a peroxisome proliferator-activated receptor Î± agonist, exerts neuroprotective effects in traumatic brain injury. Neuroscience Letters, 2005, 388, 7-12.	2.1	86
6	PPARÎ± activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochemical and Biophysical Research Communications, 2005, 338, 1818-1824.	2.1	41
7	Steroid signalling in the ovarian surface epithelium. Trends in Endocrinology and Metabolism, 2005, 16, 327-333.	7.1	35
8	The pathophysiological function of peroxisome proliferator-activated receptor-Î³ in lung-related diseases. Respiratory Research, 2005, 6, 102.	3.6	34
9	Peroxisome proliferator-activated receptors (PPARs) and ovarian function--implications for regulating steroidogenesis, differentiation, and tissue remodeling. Reproductive Biology and Endocrinology, 2005, 3, 41.	3.3	178
10	Methylamine but not mafenide mimics insulin-like activity of the semicarbazide-sensitive amine oxidase-substrate benzylamine on glucose tolerance and on human adipocyte metabolism. Pharmacological Research, 2005, 52, 475-484.	7.1	28
11	Peroxisome Proliferator-Activated Receptor-??. BioDrugs, 2006, 20, 121-135.	4.6	15
12	The Molecular Inflammatory Process in Aging. Antioxidants and Redox Signaling, 2006, 8, 572-581.	5.4	386
13	Peroxisome proliferator activated receptor-Î³ modulates reactive oxygen species generation and activation of nuclear factor-ÎºB and hypoxia-inducible factor 1Î± in allergic airway disease of mice. Journal of Allergy and Clinical Immunology, 2006, 118, 120-127.	2.9	112
14	Selectivity of fatty acid ligands for PPARÎ± which correlates both with binding to cis-element and DNA binding-independent transactivity in Caco-2 cells. Life Sciences, 2006, 80, 140-145.	4.3	28
15	The pleiotropic function of PPARÎ³ in the placenta. Molecular and Cellular Endocrinology, 2006, 249, 10-15.	3.2	88
16	HGF Enhanced Proliferation and Differentiation of Dental Pulp Cells. Journal of Endodontics, 2006, 32, 736-741.	3.1	34
17	Synthesis and evaluation of a bromine-76-labeled PPARÎ³ antagonist 2-bromo-5-nitro-N-phenylbenzamide. Nuclear Medicine and Biology, 2006, 33, 847-854.	0.6	17
18	Peroxisome Proliferator-Activated Receptors and Shock State. Scientific World Journal, The, 2006, 6, 1770-1782.	2.1	8

#	Article	IF	Citations
19	Lutein and Eicosapentaenoic Acid Interact to Modify iNOS mRNA Levels through the PPARÎ³/RXR Pathway in Chickens and HD11 Cell Lines. Journal of Nutrition, 2006, 136, 1610-1616.	2.9	70
20	Peroxisome proliferator-activated receptor-Î³ antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia*. Critical Care Medicine, 2006, 34, 1131-1138.	0.9	54
21	Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?. Fundamental and Clinical Pharmacology, 2006, 20, 429-447.	1.9	103
22	Effects of astragaloside IV on pathogenesis of metabolic syndrome in vitro1. Acta Pharmacologica Sinica, 2006, 27, 229-236.	6.1	29
23	Abnormal expression of PPAR gamma isoforms in the subcutaneous adipose tissue of patients with Cushing's disease. Clinical Endocrinology, 2006, 66, 060904075417002-???.	2.4	2
24	Peroxidated Squalene Induces the Production of Inflammatory Mediators in HaCaT Keratinocytes: A Possible Role in Acne Vulgaris. Journal of Investigative Dermatology, 2006, 126, 2430-2437.	0.7	125
25	Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-Î³ binding agents with potential application to the treatment of osteoporosis. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5659-5663.	2.2	46
26	Regulatory role for the arginineâ€“nitric oxide pathway in metabolism of energy substrates. Journal of Nutritional Biochemistry, 2006, 17, 571-588.	4.2	596
27	Metabolic effects of telmisartan in spontaneously hypertensive rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2006, 373, 264-270.	3.0	13
28	Newly developed primary culture of rat visceral adipocytes and their in vitro characteristics. Cell Biology International, 2006, 30, 381-388.	3.0	28
29	TGF-Î² Inhibition of CTL Re-Stimulation Requires Accessory Cells and Induces Peroxisome-Proliferator-Activated Receptor-Gamma (PPAR-Î³). American Journal of Transplantation, 2006, 6, 1809-1819.	4.7	2
30	The antiepileptic drug topiramate preserves metabolism-secretion coupling in insulin secreting cells chronically exposed to the fatty acid oleate. Biochemical Pharmacology, 2006, 72, 965-973.	4.4	20
31	Diabetes and mitochondrial function: Role of hyperglycemia and oxidative stress. Toxicology and Applied Pharmacology, 2006, 212, 167-178.	2.8	804
32	Peroxisome proliferator-activated receptor (PPAR)Î³ is expressed by human spermatozoa: Its potential role on the sperm physiology. Journal of Cellular Physiology, 2006, 209, 977-986.	4.1	63
33	Intestinal-specific PPARÎ³ deficiency enhances tumorigenesis in ApcMin/+ mice. International Journal of Cancer, 2006, 119, 2339-2346.	5.1	74
34	A 9-year-old male with a duplication of chromosome 3p25.3p26.2: Clinical report and gene expression analysis. American Journal of Medical Genetics, Part A, 2006, 140A, 573-579.	1.2	42
35	Peroxisome Proliferator-Activated Receptor-Gamma Is Expressed by Rat Peritoneal Mesothelial Cells: Its Potential Role in Peritoneal Cavity Local Defense. American Journal of Nephrology, 2006, 26, 602-611.	3.1	18
36	Low-Density Lipoprotein-Lowering Medication and Platelet Function. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 346-354.	0.3	23

#	Article	IF	Citations
37	Thioredoxin-Binding Protein-2-Like Inducible Membrane Protein Is a Novel Vitamin D3 and Peroxisome Proliferator-Activated Receptor (PPAR)Î³ Ligand Target Protein that Regulates PPARÎ³ Signaling. Endocrinology, 2006, 147, 733-743.	2.8	64
38	PPAR-Î³2 Pro12Ala Variant, Insulin Resistance and Plasma Long-chain Polyunsaturated Fatty Acids in Childhood Obesity. Pediatric Research, 2006, 60, 485-489.	2.3	33
39	Peroxisome Proliferator-Activated Receptor Î³ Is Highly Expressed in Pancreatic Cancer and Is Associated With Shorter Overall Survival Times. Clinical Cancer Research, 2006, 12, 6444-6451.	7.0	54
40	Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease. European Respiratory Review, 2006, 15, 211-212.	7.1	2
41	Leptin Deficiency Unmasks the Deleterious Effects of Impaired Peroxisome Proliferator-Activated Receptor Â Function (P465L PPARÂ) in Mice. Diabetes, 2006, 55, 2669-2677.	0.6	80
43	Peripheral Cytokine Expression in Autoimmune Thyroiditis: Effects ofIn VitroModulation by Rosiglitazone and Dexamethasone. Thyroid, 2006, 16, 953-960.	4.5	8
44	Modulation of Airway Remodeling and Airway Inflammation by Peroxisome Proliferator-Activated Receptor Î³ in a Murine Model of Toluene Diisocyanate-Induced Asthma. Journal of Immunology, 2006, 177, 5248-5257.	0.8	71
45	The potential of antidiabetic thiazolidinediones for anticancer therapy. Expert Opinion on Investigational Drugs, 2006, 15, 1039-1049.	4.1	42
46	Effects of Pioglitazone Versus Glipizide on Body Fat Distribution, Body Water Content, and Hemodynamics in Type 2 Diabetes. Diabetes Care, 2006, 29, 510-514.	8.6	133
47	Nitric oxide activation of peroxisome proliferatorâ€activated receptor gamma through a p38 MAPK signaling pathway. FASEB Journal, 2007, 21, 950-961.	0.5	63
48	New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand. Journal of Medical Genetics, 2007, 44, e88-e88.	3.2	32
49	RAR/RXR and PPAR/RXR Signaling in Spinal Cord Injury. PPAR Research, 2007, 2007, 1-14.	2.4	30
50	Does Lipophilicity Per Se Induce Adjuvant Effects? Methyl Palmitate as Model Substance Does Not Affect Ovalbumin Sensitization. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2007, 70, 128-137.	2.3	9
51	Fenofibrate inhibits intestinal Clâ¯ secretion by blocking basolateral KCNQ1 K+ channels. American Journal of Physiology - Renal Physiology, 2007, 293, G1288-G1299.	3.4	14
52	Involvement of PPARs in Cell Proliferation and Apoptosis in Human Colon Cancer Specimens and in Normal and Cancer Cell Lines. PPAR Research, 2007, 2007, 1-9.	2.4	43
53	MAPK- Kinases as Nucleo-Cytoplasmic Shuttles for PPARÎ³. Cell Cycle, 2007, 6, 1539-1548.	2.6	125
54	Peroxisome Proliferator-Activated Receptor-Î³ C190S Mutation Causes Partial Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2248-2255.	3.6	39
55	Metabolomic and Genetic Analysis of Biomarkers for Peroxisome Proliferator-Activated Receptor Î± Expression and Activation. Molecular Endocrinology, 2007, 21, 2136-2151.	3.7	79

#	Article	IF	Citations
56	Energy Balance, Myostatin, and GILZ: Factors Regulating Adipocyte Differentiation in Belly and Bone. PPAR Research, 2007, 2007, 1-12.	2.4	9
57	Antiadhesion effects of docosahexaenoic acid on normal human peritoneal and adhesion fibroblasts. Fertility and Sterility, 2007, 88, 1657-1662.	1.0	21
58	Rosiglitazone, a PPAR-Î³ ligand, protects against burn-induced oxidative injury of remote organs. Burns, 2007, 33, 587-593.	1.9	44
59	Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends in Immunology, 2007, 28, 551-558.	6.8	480
60	Stimulation of the peroxisome proliferator-activated receptor Î³ (PPARÎ³) and the expression of selected blood monocyte cytokine genes in diabetic macroangiopathy. Atherosclerosis, 2007, 194, e108-e115.	0.8	3
61	PPAR dual agonists: Are they opening Pandora's Box?. Pharmacological Research, 2007, 56, 91-98.	7.1	168
62	Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine. Pharmacogenomics, 2007, 8, 369-390.	1.3	44
63	Pioglitazone Inhibits Androgen Production in NCI-H295R Cells by Regulating Gene Expression of CYP17 and HSD3B2. Molecular Pharmacology, 2007, 71, 787-798.	2.3	66
64	The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Molecular Cancer, 2007, 6, 24.	19.2	663
65	Fenofibrate Represses Interleukin-17 and Interferon-Î³ Expression and Improves Colitis in Interleukin-10â€“Deficient Mice. Gastroenterology, 2007, 133, 108-123.	1.3	117
66	Anti-Atherosclerotic Activity. , 2007, , 1661-1717.		0
67	Lack of an Effect of Pioglitazone or Glipizide on Lipoprotein-Associated Phospholipase A2 in Type 2 Diabetes. Endocrine Practice, 2007, 13, 147-152.	2.1	14
68	Nutrition in the genomics era: Cardiovascular disease risk and the Mediterranean diet. Molecular Nutrition and Food Research, 2007, 51, 1293-1299.	3.3	43
69	Thiazolidinediones exhibit different effects on preadipocytes isolated from rat mesenteric fat tissue and cell line 3T3-L1 cells derived from mice. Cell Biology International, 2007, 31, 703-710.	3.0	11
70	Alternative splicing of human peroxisome proliferator-activated receptor delta (PPARdelta):effects on translation efficiency and trans-activation ability. BMC Molecular Biology, 2007, 8, 70.	3.0	20
71	Loss of the Acyl-CoA Binding Protein (Acbp) Results in Fatty Acid Metabolism Abnormalities in Mouse Hair and Skin. Journal of Investigative Dermatology, 2007, 127, 16-23.	0.7	41
72	PPARÎ± agonists inhibit nitric oxide production by enhancing iNOS degradation in LPSâ€treated macrophages. British Journal of Pharmacology, 2007, 152, 1081-1091.	5.4	32
73	Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. European Journal of Pharmacology, 2007, 561, 194-201.	3.5	66

#	Article	IF	Citations
74	15-Deoxy-Î”12,14-prostaglandin J2 down-regulates CXCR4 on carcinoma cells through PPARÎ³- and NFÎºB-mediated pathways. Experimental Cell Research, 2007, 313, 3446-3458.	2.6	23
75	Atherosclerosis and cardiovascular risk reduction with PPAR agonists. Current Atherosclerosis Reports, 2007, 9, 274-280.	4.8	9
76	Adipose Tissue Distribution and Quantification of PPARÎ²/Î´ and PPARÎ³1-3 mRNAs: Discordant Gene Expression in Subcutaneous, Retroperitoneal and Visceral Adipose Tissue of Morbidly Obese Patients. Obesity Surgery, 2007, 17, 934-940.	2.1	24
77	Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway. Molecular and Cellular Biochemistry, 2008, 317, 189-196.	3.1	44
78	Pioglitazone retrieves hepatic antioxidant DNA repair in a mice model of high fat diet. BMC Molecular Biology, 2008, 9, 82.	3.0	40
79	Increased L-CPT-1 activity and altered gene expression in pancreatic islets of malnourished adult rats: a possible relationship between elevated free fatty acid levels and impaired insulin secretion. Journal of Nutritional Biochemistry, 2008, 19, 85-90.	4.2	9
80	Quercetin pretreatment increases the bioavailability of pioglitazone in rats: Involvement of CYP3A inhibition. Biochemical Pharmacology, 2008, 75, 1670-1676.	4.4	67
81	The public road to high-quality curated biological pathways. Drug Discovery Today, 2008, 13, 856-862.	6.4	44
82	Conjugated linoleic acid increases intracellular ROS synthesis and oxygenation of arachidonic acid in macrophages. Nutrition, 2008, 24, 187-199.	2.4	32
85	Selective Activation of Peroxisome Proliferator-Activated Receptor (PPAR)Â and PPARÂ Induces Neoangiogenesis Through a Vascular Endothelial Growth Factor-Dependent Mechanism. Diabetes, 2008, 57, 1394-1404.	0.6	106
86	Genomic structure and regulation of the rat hepatic CYP4F1 gene by peroxisome proliferators. Archives of Biochemistry and Biophysics, 2008, 472, 1-16.	3.0	6
87	RAR/RXR and PPAR/RXR signaling in neurological and psychiatric diseases. Progress in Neurobiology, 2008, 85, 433-451.	5.7	84
88	Down syndrome critical region 2 protein inhibits the transcriptional activity of peroxisome proliferator-activated receptor Î² in HEK293 cells. Biochemical and Biophysical Research Communications, 2008, 376, 478-482.	2.1	9
89	Short Communication: Characterization of Madin-Darby Bovine Kidney Cell Line for Peroxisome Proliferator-Activated Receptors: Temporal Response and Sensitivity to Fatty Acids. Journal of Dairy Science, 2008, 91, 2808-2813.	3.4	35
90	Intrathecal Rosiglitazone Acts at Peroxisome Proliferatorâ€“Activated Receptor-Î³ to Rapidly Inhibit Neuropathic Pain in Rats. Journal of Pain, 2008, 9, 639-649.	1.4	87
91	Design, Synthesis, and Biological Evaluation of Novel Constrainedmeta-Substituted Phenyl Propanoic Acids as Peroxisome Proliferator-Activated Receptor Î± and Î³ Dual Agonists. Journal of Medicinal Chemistry, 2008, 51, 6318-6333.	6.4	24
92	Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrology Dialysis Transplantation, 2008, 23, 2750-2760.	0.7	118
93	Rosiglitazone Attenuates Allergic Inflammation and Inhibits Expression of Galectin-3 in a Mouse Model of Allergic Rhinitis. Journal of International Medical Research, 2008, 36, 830-836.	1.0	15

#	Article	IF	Citations
94	Endothelial Progenitor Cells and Angiogenesis Join the PPARty. Circulation Research, 2008, 103, 7-9.	4.5	6
95	Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride. Diabetes and Vascular Disease Research, 2008, 5, 168-176.	2.0	16
96	Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk: a Long Island ancillary study. Carcinogenesis, 2008, 29, 1944-1949.	2.8	25
97	In Vivo Imaging Reveals Selective Peroxisome Proliferator Activated Receptor Modulator Activity of the Synthetic Ligand 3-(1-(4-Chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886). Molecular Pharmacology, 2008, 73, 1434-1443.	2.3	33
98	Genetic variants in peroxisome proliferator-activated receptor-Î³ gene are associated with risk of lung cancer in a Chinese population. Carcinogenesis, 2008, 29, 342-350.	2.8	24
99	Role of the Peroxisome Proliferator-Activated Receptors, Adenosine Monophosphate-Activated Kinase, and Adiponectin in the Ovary. PPAR Research, 2008, 2008, 1-9.	2.4	41
100	PPARs and the kidney in metabolic syndrome. American Journal of Physiology - Renal Physiology, 2008, 294, F1032-F1047.	2.7	89
101	PTEN as a Unique Promising Therapeutic Target for Occupational Asthma. Immunopharmacology and Immunotoxicology, 2008, 30, 793-814.	2.4	7
102	Flaxseed lignan attenuates high-fat diet-induced fat accumulation and induces adiponectin expression in mice. British Journal of Nutrition, 2008, 100, 669-676.	2.3	112
103	Involvement of PPARÎ± in the growth inhibitory effect of arachidonic acid on breast cancer cells. British Journal of Nutrition, 2008, 100, 739-750.	2.3	24
104	Peroxisome Proliferator-Activated Receptors as Novel Targets in Lung Disease*. Chest, 2008, 134, 152-157.	0.8	2
105	Impact of PUFA on early immune and fetal development. British Journal of Nutrition, 2008, 100, 1158-1168.	2.3	42
106	Peroxisome Proliferator-Activated Receptors as Novel Targets in Lung Disease<xref rid="AFF1">[*]</xref>. Chest, 2008, 134, 152.	0.8	62
109	Ectopic expression of porcine peroxisome proliferator-activated receptor Î´ regulates adipogenesis in mouse myoblasts1. Journal of Animal Science, 2008, 86, 64-72.	0.5	34
110	Peroxisome Proliferator-Activated Receptors: â€œKeyâ€•Regulators of Neuroinflammation after Traumatic Brain Injury. PPAR Research, 2008, 2008, 1-7.	2.4	38
111	Comparison of cytokine modulation by natural peroxisome proliferatorâ€“activated receptor Î³ ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cellsâ€”potential for dietary modulation of peroxisome proliferatorâ€“activated receptor Î³ in intestinal inflammation. American Journal of Clinical Nutrition, 2008, 87, 939-948.	4.7	107
112	Macrophages, PPARs, and Cancer. PPAR Research, 2008, 2008, 1-11.	2.4	41
113	CXCR4 in Cancer and Its Regulation by PPARÎ³. PPAR Research, 2008, 2008, 1-19.	2.4	18

#	Article	IF	Citations
114	PPAR<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>and MEK Interactions in Cancer. PPAR Research, 2008, 2008, 1-16.	2.4	49
115	Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Research, 2008, 2008, 1-14.	2.4	71
116	Renal Hypoxia and Dysoxia After Reperfusion of the Ischemic Kidney. Molecular Medicine, 2008, 14, 502-516.	4.4	241
117	Cross-Talk between PPAR<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>and Insulin Signaling and Modulation of Insulin Sensitivity. PPAR Research, 2009, 2009, 1-12.	2.4	162
118	Reducing without Side Effects? A Novel Strategy for Designing the PPAR Agonists. , 2009, , .		1
119	Deletion of PPARÎ³ in Alveolar Macrophages Is Associated with a Th-1 Pulmonary Inflammatory Response. Journal of Immunology, 2009, 182, 5816-5822.	0.8	106
120	Coadministration of muraglitazar plus glyburide: Improvement of glycaemic and lipid profiles in patients with type 2 diabetes. Diabetes and Vascular Disease Research, 2009, 6, 120-132.	2.0	3
121	Peroxisome Proliferator-Activated Receptor Î³ Agonist Down-Regulates IL-17 Expression in a Murine Model of Allergic Airway Inflammation. Journal of Immunology, 2009, 183, 3259-3267.	0.8	75
122	Roles of NF-ÎºB Activation and Peroxisome Proliferator-Activated Receptor Gamma Inhibition in the Effect of Rifampin on Inducible Nitric Oxide Synthase Transcription in Human Lung Epithelial Cells. Antimicrobial Agents and Chemotherapy, 2009, 53, 1539-1545.	3.2	16
123	Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. , 2009, 122, 246-263.		127
124	Rapid pain modulation with nuclear receptor ligands. Brain Research Reviews, 2009, 60, 114-124.	9.0	55
125	Peroxisome proliferator-activated receptor gamma activates fas ligand gene promoter inducing apoptosis in human breast cancer cells. Breast Cancer Research and Treatment, 2009, 113, 423-434.	2.5	60
126	Chronic intracerebroventricular injection of TLQP-21 prevents high fat diet induced weight gain in fast weight-gaining mice. Genes and Nutrition, 2009, 4, 49-57.	2.5	30
127	The effect of trans-10, cis-12 conjugated linoleic acid on gene expression profiles related to lipid metabolism in human intestinal-like Caco-2 cells. Genes and Nutrition, 2009, 4, 103-112.	2.5	8
128	Dietary fatty acid quality affects AR and PPARÎ³ levels and prostate growth. Prostate, 2009, 69, 548-558.	2.3	45
130	Nuclear receptors as therapeutic targets in cholestatic liver diseases. British Journal of Pharmacology, 2009, 156, 7-27.	5.4	143
131	Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. British Journal of Pharmacology, 2009, 158, 994-1003.	5.4	101
132	Regulation of adipogenesis by medium-chain fatty acids in the absence of hormonal cocktail. Journal of Nutritional Biochemistry, 2009, 20, 537-543.	4.2	25

#	Article	IF	Citations
133	Transcriptional regulation of hepatic stellate cells. Advanced Drug Delivery Reviews, 2009, 61, 497-512.	13.7	97
134	Folic Acid Supplementation during the Juvenile-Pubertal Period in Rats Modifies the Phenotype and Epigenotype Induced by Prenatal Nutrition. Journal of Nutrition, 2009, 139, 1054-1060.	2.9	183
135	Triphenyltin alters lipid homeostasis in females of the ramshorn snail Marisa cornuarietis. Environmental Pollution, 2009, 157, 1714-1720.	7.5	28
136	Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits insulin receptor signalling in HTC rat hepatoma cells. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 740-745.	2.4	24
137	Peroxisome proliferator-activated receptors and angiogenesis. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 751-759.	2.6	56
138	Amelioration of pulmonary dysfunction and neutrophilic inflammation by PPARÎ³ agonist in LPS-exposed guinea pigs. Pulmonary Pharmacology and Therapeutics, 2009, 22, 183-189.	2.6	25
139	Anti-inflammatory Effect of Peroxisome Proliferator Activated Receptor Gamma on Human Dental Pulp Cells. Journal of Endodontics, 2009, 35, 524-528.	3.1	30
140	PPAR-Î± modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma. Pharmacological Research, 2009, 59, 338-350.	7.1	38
141	Two-dimensional gel proteome reference map of human small intestine.. Proteome Science, 2009, 7, 10.	1.7	8
142	Increased hepatic oxidative metabolism distinguishes the action of Peroxisome proliferator-activated receptor Î´ from Peroxisome proliferator-activated receptor Î³ in the ob/ob mouse. Genome Medicine, 2009, 1, 115.	8.2	32
143	The Protective Role of Per2 Against Carbon Tetrachloride-Induced Hepatotoxicity. American Journal of Pathology, 2009, 174, 63-70.	3.8	37
144	Human Urinary Metabolomic Profile of PPARÎ± Induced Fatty Acid Î²-Oxidation. Journal of Proteome Research, 2009, 8, 4293-4300.	3.7	55
145	Synthesis and Biological Evaluation of 2-Heteroarylthioalkanoic Acid Analogues of Clofibric Acid as Peroxisome Proliferator-Activated Receptor Î± Agonists. Journal of Medicinal Chemistry, 2009, 52, 6224-6232.	6.4	22
146	Rosiglitazone, a PPAR-Î³ Ligand, Reduces Burn Progression in Rats. Journal of Burn Care and Research, 2009, 30, 499-504.	0.4	16
147	Preventing Type 2 Diabetes Mellitus: Room for Residual Risk Reduction After Lifestyle Changes?. Current Pharmaceutical Design, 2010, 16, 3839-3847.	1.9	11
148	Identification of (Î²-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor Î³ activity. European Journal of Medicinal Chemistry, 2010, 45, 193-202.	5.5	27
149	Drug synergism of antihypertensive action in combination of telmisartan with lercanidipine in spontaneous hypertensive rats. Archives of Pharmacal Research, 2010, 33, 1411-1418.	6.3	8
150	SIRT1 Transcription Is Decreased in Visceral Adipose Tissue of Morbidly Obese Patients with Severe Hepatic Steatosis. Obesity Surgery, 2010, 20, 633-639.	2.1	91

#	Article	IF	Citations
151	Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. , 2010, 126, 228-243.		79
152	Interleukin-17 regulation: an attractive therapeutic approach for asthma. Respiratory Research, 2010, 11, 78.	3.6	72
153	PPARÎ³2 expression in growth plate chondrocytes is regulated by p38 and GSKâ€3. Journal of Cellular and Molecular Medicine, 2010, 14, 242-256.	3.6	12
154	Serum regulates adipogenesis of mesenchymal stem cells via MEK/ERKâ€dependent PPARÎ³ expression and phosphorylation. Journal of Cellular and Molecular Medicine, 2010, 14, 922-932.	3.6	41
155	From Machine Learning to Natural Product Derivatives that Selectively Activate Transcription Factor PPARÎ³. ChemMedChem, 2010, 5, 191-194.	3.2	58
156	PPARÎ³ inhibits inflammatory reaction in oxidative stress induced human diploid fibloblast. Cell Biochemistry and Function, 2010, 28, 490-496.	2.9	35
157	Cannabinoid effects on CB1 receptor density in the adolescent brain: An autoradiographic study using the synthetic cannabinoid HU210. Synapse, 2010, 64, 845-854.	1.2	43
158	Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutrition Reviews, 2010, 68, 280-289.	5.8	898
159	Non-Steroidal Anti-Inflammatory Drugs in the Carcinogenesis of the Gastrointestinal Tract. Pharmaceuticals, 2010, 3, 2495-2516.	3.8	8
160	Nitric Oxide in Airway Inflammation. , 2010, , 795-812.		0
161	PPAR Signaling Pathway and Cancer-Related Proteins Are Involved in Celiac Disease-Associated Tissue Damage. Molecular Medicine, 2010, 16, 199-209.	4.4	47
162	PPARÎ³ as a potential therapeutic target in pulmonary hypertension. Therapeutic Advances in Respiratory Disease, 2010, 4, 143-160.	2.6	43
163	Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4147-4152.	7.1	106
164	Phytochemicals as Modulators of PPARs and RXRs. PPAR Research, 2010, 2010, 1-2.	2.4	14
165	PPARs and Anticancer Therapies. PPAR Research, 2010, 2010, 1-2.	2.4	5
166	Therapeutic Implications of PPAR<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>Î³</mml:mi></mml:math>in Human Osteosarcoma. PPAR Research, 2010, 2010, 1-16.	2.4	43
167	Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities. Therapeutic Advances in Chronic Disease, 2010, 1, 43-57.	2.5	11
168	Use of transgenic mice in UDP-glucuronosyltransferase (UGT) studies. Drug Metabolism Reviews, 2010, 42, 123-131.	3.6	7

#	Article	IF	Citations
169	Endothelium-Dependent Vasodilator Effects of Peroxisome Proliferator-Activated Receptor Î² Agonists via the Phosphatidyl-Inositol-3 Kinase-Akt Pathway. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 554-561.	2.5	50
170	Mycobacterium tuberculosis Activates Human Macrophage Peroxisome Proliferator-Activated Receptor Î³ Linking Mannose Receptor Recognition to Regulation of Immune Responses. Journal of Immunology, 2010, 185, 929-942.	0.8	210
171	Relationship between Environmental Phthalate Exposure and the Intelligence of School-Age Children. Environmental Health Perspectives, 2010, 118, 1027-1032.	6.0	212
172	Thiazolidinediones alter growth and epithelial cell integrity, independent of PPAR-Î³ and MAPK activation, in mouse M1 cortical collecting duct cells. American Journal of Physiology - Renal Physiology, 2010, 298, F1105-F1112.	2.7	3
173	Effects of Glycyrrhizic Acid on Peroxisome Proliferator-Activated Receptor Gamma (PPAR<mml:math) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Lipase (LPL), Serum Lipid and HOMA-IR in Rats. PPAR Research, 2010, 2010, 1-6.	2.4	33
174	Amelioration of Insulin Resistance by Scopoletin in High-Glucose-Induced, Insulin-Resistant HepG2 Cells. Hormone and Metabolic Research, 2010, 42, 930-935.	1.5	45
175	Nuclear Receptor Regulation of the Adaptive Response of Bile Acid Transporters in Cholestasis. Seminars in Liver Disease, 2010, 30, 160-177.	3.6	90
176	CXCL9 and CXCL11 Chemokines Modulation by Peroxisome Proliferator-Activated Receptor-Î± Agonists Secretion in Gravesâ€™ and Normal Thyrocytes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E413-E420.	3.6	61
177	Oleoylethanolamide affects food intake and sleepâ€“waking cycle through a hypothalamic modulation. Pharmacological Research, 2010, 61, 379-384.	7.1	25
178	PPARs: Important Regulators in Metabolism and Inflammation. , 2010, , 259-285.		1
179	Activation of peroxisome proliferator-activated receptor Î³ in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema. Neuropharmacology, 2010, 58, 337-345.	4.1	58
180	Abdominal subcutaneous adipose tissue morphology in a patient with a dominant-negative mutation (P467L) in the nuclear receptor peroxisome proliferator-activated receptor-gamma (PPARG) gene. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, e11-e12.	2.6	2
181	Novel Findings in Drug-Induced Dendritic Cell Tolerogenicity. International Reviews of Immunology, 2010, 29, 574-607.	3.3	28
182	An Omics Perspective on Cancer Research. , 2010, , .		20
183	Peroxisome proliferator-activated receptors (PPARs)-independent functions of fish oil on glucose and lipid metabolism in diet-induced obese mice. Lipids in Health and Disease, 2010, 9, 101.	3.0	14
184	Mulberry Leaf Polyphenols Possess Antiatherogenesis Effect via Inhibiting LDL Oxidation and Foam Cell Formation. Journal of Agricultural and Food Chemistry, 2011, 59, 1985-1995.	5.2	64
185	Multiple Sclerosis is Not a Disease of the Immune System. Quarterly Review of Biology, 2011, 86, 287-321.	0.1	48
186	The contrasting roles of PPARÎ´ and PPARÎ³ in regulating the metabolic switch between oxidation and storage of fats in white adipose tissue. Genome Biology, 2011, 12, R75.	9.6	85

#	Article	IF	Citations
187	Conjugated Linoleic Acid Regulates Phosphorylation of PPARÎ³ by Modulation of ERK 1/2 and p38 Signaling in Human Macrophages/Fatty Acid-Laden Macrophages. Journal of Agricultural and Food Chemistry, 2011, 59, 11846-11852.	5.2	9
188	Trans-10, cis-12 conjugated linoleic acid and the PPAR-Î³ agonist rosiglitazone attenuate lipopolysaccharide-induced TNF-Î± production by bovine immune cells. Domestic Animal Endocrinology, 2011, 41, 118-125.	1.6	22
189	Pioglitazone modulates the balance of effector and regulatory T cells in apolipoprotein E deficient miceâ˜†. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 25-32.	2.6	10
190	BiochaninÃ¯Â¿Â½A ameliorates the cytokine secretion profile of lipopolysaccharide-stimulated macrophages by a PPARÎ³-dependent pathway. Molecular Medicine Reports, 2012, 5, 217-22.	2.4	27
191	Reduction of body weight, liver steatosis and expression of stearoylâ€CoA desaturase 1 by the isoflavone daidzein in dietâ€induced obesity. British Journal of Pharmacology, 2011, 164, 1899-1915.	5.4	84
192	Morphological and Receptorial Changes in the Epididymal Adipose Tissue of Rats Subjected to a Stressful Stimulus. Obesity, 2011, 19, 703-708.	3.0	15
193	Discovery of gemfibrozil analogues that activate PPARÎ± and enhance the expression of gene CPT1A involved in fatty acids catabolism. European Journal of Medicinal Chemistry, 2011, 46, 5218-5224.	5.5	28
194	Lycium barbarum (Goji Berry) extracts and its taurine component inhibit PPAR-Î³-dependent gene transcription in human retinal pigment epithelial cells: Possible implications for diabetic retinopathy treatment. Biochemical Pharmacology, 2011, 82, 1209-1218.	4.4	53
195	Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARÎ± antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4869-4872.	2.2	31
196	A mÃ©nage Ã trois made in heaven: G-protein-coupled receptors, lipids and TRP channels. Cell Calcium, 2011, 50, 9-26.	2.4	38
197	Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes. Molecular and Cellular Biochemistry, 2011, 358, 355-363.	3.1	37
198	Pioglitazone inhibits TGFÎ² induced keratocyte transformation to myofibroblast and extracellular matrix production. Molecular Biology Reports, 2011, 38, 4501-4508.	2.3	22
199	Troglitazone-activated PPARÎ³ inhibits LPS-induced lung alveolar type II epithelial cells injuries via TNF-Î±. Molecular Biology Reports, 2011, 38, 5009-5015.	2.3	9
200	In silico structure-based drug design approach to develop novel pharmacophore model of human peroxisome proliferator-activated receptor Î³ agonists. Medicinal Chemistry Research, 2011, 20, 656-659.	2.4	8
201	Is the effect of high fat diet on lipid and carbohydrate metabolism related to inflammation?. Mediterranean Journal of Nutrition and Metabolism, 2011, 4, 203-209.	0.5	3
202	Resveratrol Upregulated SIRT1, FOXO1, and Adiponectin and Downregulated PPARÎ³1â€“3 mRNA Expression in Human Visceral Adipocytes. Obesity Surgery, 2011, 21, 356-361.	2.1	84
203	Prediction of the PPARÎ± agonism of fibrates by combined MMâ€“docking approaches. Journal of Molecular Graphics and Modelling, 2011, 29, 865-875.	2.4	4
204	The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor. Current Pharmaceutical Design, 2011, 17, 3202-3216.	1.9	39

#	Article	IF	Citations
205	Hypercholesterolemia: Chemical Aspect of Approach. Current Medicinal Chemistry, 2011, 18, 4076-4105.	2.4	3
206	The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD). Current Medicinal Chemistry, 2011, 18, 3306-3313.	2.4	93
207	Ameliorative Effects of GW1929, a Nonthiazolidinedione PPARγ Agonist,on Inflammation and Apoptosis in Focal Cerebral Ischemic-Reperfusion Injury. Current Neurovascular Research, 2011, 8, 236-245.	1.1	22
208	Biological Function and Prognostic Significance of Peroxisome Proliferator-Activated Receptor Î´ in Rectal Cancer. Clinical Cancer Research, 2011, 17, 3760-3770.	7.0	44
209	Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARÎ³ and histone acetylation. Journal of Lipid Research, 2011, 52, 759-770.	4.2	42
210	Decrease of Blood Lipids Induced by Shan-Zha (Fruit of Crataegus pinnatifida) is Mainly Related to an Increase of PPARÎ± in Liver of Mice Fed High-Fat Diet. Hormone and Metabolic Research, 2011, 43, 625-630.	1.5	43
211	Changes in the 24â€‰h Rhythmicity of Liver PPARs and Peroxisomal Markers When Feeding Is Restricted to Two Daytime Hours. PPAR Research, 2011, 2011, 1-11.	2.4	16
212	Peroxisome Proliferatorâ€Activated Receptorâ€“Î³ Agonist Induces Regulatory T Cells in a Murine Model of Allergic Rhinitis. Otolaryngology - Head and Neck Surgery, 2011, 144, 506-513.	1.9	29
213	PPARÎ³Expression and Function in Mycobacterial Infection: Roles in Lipid Metabolism, Immunity, and Bacterial Killing. PPAR Research, 2012, 2012, 1-7.	2.4	78
214	The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H515-H526.	3.2	76
215	Peroxisome Proliferator-Activated Receptors in Regulation of Cytochromes P450: New Way to Overcome Multidrug Resistance?. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-10.	3.0	16
216	Docking, Synthesis and Anti-Diabetic Activity of Novel Sulfonylhydrazone Derivatives Designed as PPAR-Gamma Agonists. Current Topics in Medicinal Chemistry, 2012, 12, 2037-2048.	2.1	14
217	Cloning and expression profiles of yak lipoprotein lipase gene. Journal of Applied Animal Research, 2012, 40, 311-315.	1.2	2
218	Renoprotective Effect of Pioglitazone by the Prevention of Glomerular Hyperfiltration through the Possible Restoration of Altered Macula Densa Signaling in Rats with Type 2 Diabetic Nephropathy. Nephron Experimental Nephrology, 2013, 122, 83-94.	2.2	11
219	Nuclear Receptors in Nonalcoholic Fatty Liver Disease. Journal of Lipids, 2012, 2012, 1-10.	4.8	30
220	The Synthetic Cannabinoid R(+)WIN55,212-2 Augments Interferon-Î² Expression via Peroxisome Proliferator-activated Receptor-Î±. Journal of Biological Chemistry, 2012, 287, 25440-25453.	3.4	17
221	Red clover extract exerts antidiabetic and hypolipidemic effects in db/db mice. Experimental and Therapeutic Medicine, 2012, 4, 699-704.	1.8	14
222	Methodologies for Investigating Natural Medicines for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). Current Pharmaceutical Biotechnology, 2012, 13, 278-291.	1.6	24

#	Article	IF	Citations
223	Peroxisome proliferator-activated receptor-alpha agonists repress expression of thrombin-activatable fibrinolysis inhibitor by decreasing transcript stability. Thrombosis and Haemostasis, 2012, 108, 74-85.	3.4	7
224	Reduced Peroxisome Proliferator-Activated Receptor Î± Expression Is Associated With Decreased Survival and Increased Tissue Bacterial Load in Sepsis. Shock, 2012, 37, 164-169.	2.1	68
225	Î”⁹â€tetrahydrocannabinol (Î”⁹â€THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathology and Applied Neurobiology, 2012, 38, 535-547.	3.2	84
226	Triglyceride-Rich Lipoprotein Regulates APOB48 Receptor Gene Expression in Human THP-1 Monocytes and Macrophages3. Journal of Nutrition, 2012, 142, 227-232.	2.9	22
227	Sperm metabolism in pig: a role for peroxisome proliferator-activated receptor (PPAR)Î³. Journal of Experimental Biology, 2013, 216, 1085-92.	1.7	24
228	Investigation of Polymorphic Variants ofPPARDandAPOEGenes in Turkish Coronary Heart Disease Patients. DNA and Cell Biology, 2012, 31, 867-875.	1.9	10
229	The meta-analysis of the association of PPARG P12A, C161T polymorphism and coronary heart disease. Wiener Klinische Wochenschrift, 2012, 124, 671-677.	1.9	17
230	Obesity and metabolic syndrome: Future therapeutics based on novel molecular pathways. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2012, 24, 204-211.	0.8	2
231	Organ fibrosis inhibited by blocking transforming growth factor-Î² signaling via peroxisome proliferator-activated receptor Î³ agonists. Hepatobiliary and Pancreatic Diseases International, 2012, 11, 467-478.	1.3	53
232	Synthesis and structureâ€“activity relationships of fibrate-based analogues inside PPARs. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7662-7666.	2.2	31
233	Unsaturated Fatty Alcohol Derivatives of Olive Oil Phenolic Compounds with Potential Low-Density Lipoprotein (LDL) Antioxidant and Antiobesity Properties. Journal of Agricultural and Food Chemistry, 2012, 60, 1067-1074.	5.2	17
234	Submaximal PPARÎ³ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders. British Journal of Pharmacology, 2012, 166, 1981-1992.	5.4	69
235	PPARÎ± activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4. Archives of Biochemistry and Biophysics, 2012, 518, 71-78.	3.0	28
236	The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy. BMC Ophthalmology, 2012, 12, 46.	1.4	9
237	Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-Î±. Journal of Neuroinflammation, 2012, 9, 81.	7.2	52
238	Peroxisome proliferator-activated receptor gamma modulation and lipogenic response in adipocytes of small-for-gestational age offspring. Nutrition and Metabolism, 2012, 9, 62.	3.0	20
239	Effect of ginseng polysaccharide on the urinary excretion of type 2 diabetic rats studied by liquid chromatographyâ€“mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 907, 7-12.	2.3	40
240	n-3 Dietary supplementation and lipid metabolism: Differences between vegetable- and fish-derived oils. Journal of Functional Foods, 2012, 4, 207-212.	3.4	22

#	Article	IF	Citations
241	Cyanidin 3-O-Î²-d-glucoside-rich blackberries modulate hepatic gene expression, and anti-obesity effects in ovariectomized rats. Journal of Functional Foods, 2012, 4, 480-488.	3.4	50
242	Emerging drugs for chronic obstructive pulmonary disease. Expert Opinion on Emerging Drugs, 2012, 17, 61-82.	2.4	22
243	Regulation of prostacyclin synthase expression and prostacyclin content in the pig endometrium. Theriogenology, 2012, 78, 2071-2086.	2.1	19
244	Structural Insights into Human Peroxisome Proliferator Activated Receptor Delta (PPAR-Delta) Selective Ligand Binding. PLoS ONE, 2012, 7, e33643.	2.5	43
245	Effect of 2-methyl-2-phenoxy propionic acid on serum lipid profile and ovarian activity in dairy cows. Czech Journal of Animal Science, 2012, 57, 550-556.	1.3	6
246	Vascular inflammation is a missing link for diabetes-enhanced atherosclerotic cardiovascular diseases. Frontiers in Bioscience - Landmark, 2012, 17, 1140.	3.0	9
247	Red Clover Extract Ameliorates Dyslipidemia in Streptozotocinâ€induced Diabetic C57BL/6 Mice by Activating Hepatic PPARÎ±. Phytotherapy Research, 2012, 26, 860-864.	5.8	31
248	Antiobesity Effects of a Sulfur Compound Thiacremonone Mediated via Downâ€regulation of Serum Triglyceride and Glucose Levels and Lipid Accumulation in the Liver of db/db Mice. Phytotherapy Research, 2012, 26, 1265-1271.	5.8	24
249	PPARÎ³ activation by baicalin suppresses NF-ÎºB-mediated inflammation in aged rat kidney. Biogerontology, 2012, 13, 133-145.	3.9	60
250	5,7â€Dimethoxyflavone, an activator of PPARÎ±/Î³, inhibits UVBâ€induced MMP expression in human skin fibroblast cells. Experimental Dermatology, 2012, 21, 211-216.	2.9	49
251	Anti-inflammatory mechanism of PPARÎ³ on LPS-induced pulp cells: Role of the ROS removal activity. Archives of Oral Biology, 2012, 57, 392-400.	1.8	53
252	Bidirectional fluorescence properties of pyrene-based peroxisome proliferator-activated receptor (PPAR) Î±/Î´ dual agonist. Bioorganic and Medicinal Chemistry, 2012, 20, 3460-3464.	3.0	6
253	PPAR-Gamma Agonist Rosiglitazone Attenuates the Inflammation Caused by Carrageenan in the Mouse Model of Pleurisy. Inflammation, 2012, 35, 280-288.	3.8	12
254	A High-Fat Diet Increases IL-1, IL-6, and TNF-Î± Production by Increasing NF-ÎºB and Attenuating PPAR-Î³ Expression in Bone Marrow Mesenchymal Stem Cells. Inflammation, 2013, 36, 379-386.	3.8	129
255	Towards a humanized PPARÎ³ reporter system for in vivo screening of obesogens. Molecular and Cellular Endocrinology, 2013, 374, 1-9.	3.2	15
256	Disparity in actions of rosiglitazone against cisplatin-induced nephrotoxicity in female Sprague-Dawley rats. Environmental Toxicology and Pharmacology, 2013, 36, 883-890.	4.0	8
257	The involvement of peroxisome proliferator activated receptors (PPARs) in prostaglandin F2Î± production by porcine endometrium. Reproductive Biology, 2013, 13, 309-316.	1.9	10
258	The Survival Role of Peroxisome Proliferator-activated Receptor Gamma Induces Odontoblast Differentiation against Oxidative Stress in Human Dental Pulp Cells. Journal of Endodontics, 2013, 39, 236-241.	3.1	43

#	Article	IF	Citations
259	Cilostazol improves the response to ischemia in diabetic mice by a mechanism dependent on PPARÎ³. Molecular and Cellular Endocrinology, 2013, 381, 80-87.	3.2	23
260	The nuances of atherogenic dyslipidemia in diabetes: Focus on triglycerides and current management strategies. Indian Heart Journal, 2013, 65, 683-690.	0.5	10
261	Clostridium Butyricum MIYAIRI 588 Improves High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats. Digestive Diseases and Sciences, 2013, 58, 3534-3544.	2.3	63
262	PPARÎ³ inhibits inflammation and RANKL expression in epoxy resin-based sealer-induced osteoblast precursor cells E1 cells. Archives of Oral Biology, 2013, 58, 28-34.	1.8	17
263	Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes. Gene, 2013, 523, 20-26.	2.2	21
264	Activation of PPAR-Î± induces cell cycle arrest and inhibits transforming growth factor-Î²1 induction of smooth muscle cell phenotype in 10T1/2 mesenchymal cells. Cellular Signalling, 2013, 25, 1252-1263.	3.6	12
265	Azelaic acid reduced senescenceâ€like phenotype in photoâ€irradiated human dermal fibroblasts: possible implication of PPARÎ³. Experimental Dermatology, 2013, 22, 41-47.	2.9	45
266	The C161T polymorphism in the peroxisome proliferator-activated receptor gamma gene (PPARÎ³) is associated with risk of coronary artery disease: a meta-analysis. Molecular Biology Reports, 2013, 40, 3101-3112.	2.3	21
267	Lowâ€Level Laser Therapy Restores the Oxidative Stress Balance in Acute Lung Injury Induced by Gut Ischemia and Reperfusion. Photochemistry and Photobiology, 2013, 89, 179-188.	2.5	68
268	Insights into the Activity, Differential Expression, Mutual Regulation, and Functions of Matrix Metalloproteinases and A Disintegrin and Metalloproteinases in Hypertension and Cardiac Disease. Journal of Vascular Research, 2013, 50, 52-68.	1.4	23
269	Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases. Clinics in Liver Disease, 2013, 17, 161-189.	2.1	87
270	Molecular Mechanism of Peroxisome Proliferator-Activated Receptor Î± Activation by WY14643: a New Mode of Ligand Recognition and Receptor Stabilization. Journal of Molecular Biology, 2013, 425, 2878-2893.	4.2	101
271	High levels of arachidonic acid and peroxisome proliferator-activated receptor-alpha in breast cancer tissues are associated with promoting cancer cell proliferation. Journal of Nutritional Biochemistry, 2013, 24, 274-281.	4.2	61
272	Monascus-Fermented Yellow Pigments Monascin and Ankaflavin Showed Antiobesity Effect via the Suppression of Differentiation and Lipogenesis in Obese Rats Fed a High-Fat Diet. Journal of Agricultural and Food Chemistry, 2013, 61, 1493-1500.	5.2	68
273	A maternal diet of fatty fish reduces body fat of offspring compared with a maternal diet of beef and a postâ€weaning diet of fish improves insulin sensitivity and lipid profile in adult <scp>C</scp>57<scp>BL</scp>/6 male mice. Acta Physiologica, 2013, 209, 220-234.	3.8	25
274	Effects of peroxisome proliferator-activated receptor-Î² activation in endothelin-dependent hypertension. Cardiovascular Research, 2013, 99, 622-631.	3.8	23
275	Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases. Mediators of Inflammation, 2013, 2013, 1-18.	3.0	257
276	Therapeutic Implications of Targeting Energy Metabolism in Breast Cancer. PPAR Research, 2013, 2013, 1-11.	2.4	11

#	Article	IF	Citations
277	Inflammation and Oxidative Stress in Diabetic Nephropathy: New Insights on Its Inhibition as New Therapeutic Targets. Journal of Diabetes Research, 2013, 2013, 1-8.	2.3	139
278	Peroxisome proliferator-activated receptor (PPAR) isoforms in coronary heart disease. Turkish Journal of Biochemistry, 2013, 38, 372-384.	0.5	2
279	Activated Cyclin-Dependent Kinase 5 Promotes Microglial Phagocytosis of Fibrillar Î²-Amyloid by Up-regulating Lipoprotein Lipase Expression. Molecular and Cellular Proteomics, 2013, 12, 2833-2844.	3.8	51
280	Anti-Obesity Effect and Action Mechanism ofAdenophora triphyllaRoot Ethanol Extract in C57BL/6 Obese Mice Fed a High-Fat Diet. Bioscience, Biotechnology and Biochemistry, 2013, 77, 544-550.	1.3	26
282	Protective Effect of Pioglitazone on Retinal Ischemia/Reperfusion Injury in Rats. , 2013, 54, 3912.		32
283	Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism. Hepatology, 2013, 58, 1881-1884.	7.3	10
284	Enhanced Anti-Obesity Activities of Red Mold Dioscorea When Fermented Using Deep Ocean Water as the Culture Water. Marine Drugs, 2013, 11, 3902-3925.	4.6	18
285	Effect of Moringa oleifera on advanced glycation end-product formation and lipid metabolism gene expression in HepG2 cells. Genetics and Molecular Research, 2014, 13, 723-735.	0.2	35
286	The effect of nutrition and metabolic status on the development of follicles, oocytes and embryos in ruminants. Animal, 2014, 8, 1031-1044.	3.3	61
287	Peroxisome proliferator-activated receptor Î± activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway. Cell Death and Disease, 2014, 5, e1397-e1397.	6.3	95
288	Exendin-4 Improves Nonalcoholic Fatty Liver Disease by Regulating Glucose Transporter 4 Expression in ob/ob Mice. Korean Journal of Physiology and Pharmacology, 2014, 18, 333.	1.2	23
289	Evaluation of peroxisome proliferatorâ€activated receptor agonists on interleukinâ€5â€induced eosinophil differentiation. Immunology, 2014, 142, 484-491.	4.4	6
290	Docosahexaenoic acid reduces linoleic acid induced monocyte chemoattractant proteinâ€1 expression via PPARÎ³Âand nuclear factorâ€ÎºB pathway in retinal pigment epithelial cells. Molecular Nutrition and Food Research, 2014, 58, 2053-2065.	3.3	19
291	Activation of Peroxisome Proliferatorâ€activated Receptor Gamma Leads to Upregulation of <scp>ESE</scp>â€3 Expression in Human Monocyteâ€derived Dendritic Cells. Scandinavian Journal of Immunology, 2014, 79, 20-26.	2.7	5
292	Inducing Effect of Clofibric Acid on Stearoylâ€CoA Desaturase in Intestinal Mucosa of Rats. Lipids, 2014, 49, 1203-1214.	1.7	5
293	Fibrate treatment for primary biliary cirrhosis. Current Opinion in Gastroenterology, 2014, 30, 279-286.	2.3	36
294	Role of PPARÎ³in the Differentiation and Function of Neurons. PPAR Research, 2014, 2014, 1-9.	2.4	54
295	Minireview: Challenges and Opportunities in Development of PPAR Agonists. Molecular Endocrinology, 2014, 28, 1756-1768.	3.7	138

#	Article	IF	Citations
296	Down-regulation of PPARÎ± in the spinal cord contributes to augmented peripheral inflammation and inflammatory hyperalgesia in diet-induced obese rats. Neuroscience, 2014, 278, 165-178.	2.3	22
297	Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARÎ³): a review. Biochemical Pharmacology, 2014, 92, 73-89.	4.4	492
298	Molecular determinants for improved activity at PPARÎ±: Structureâ€“activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARÎ±. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4048-4052.	2.2	7
299	Variable effects of 12 weeks of omega-3 supplementation on resting skeletal muscle metabolism. Applied Physiology, Nutrition and Metabolism, 2014, 39, 1083-1091.	1.9	27
300	Polymorphisms of peroxisome proliferator-activated receptors and survival of lung cancer and upper aero-digestive tract cancers. Lung Cancer, 2014, 85, 449-456.	2.0	9
301	Transgenic expression of salmon delta-5 and delta-6 desaturase in zebrafish muscle inhibits the growth of Vibrio alginolyticus and affects fish immunomodulatory activity. Fish and Shellfish Immunology, 2014, 39, 223-230.	3.6	24
302	Effect of Trifolium pratense extract on methionine-choline-deficient diet-induced steatohepatitis in C57BL/6 mice. Chinese Journal of Natural Medicines, 2014, 12, 194-198.	1.3	11
303	Resveratrol protects RPE cells from sodium iodate by modulating PPARÎ± and PPARÎ´. Experimental Eye Research, 2014, 118, 100-108.	2.6	27
304	WIN induces apoptotic cell death in human colon cancer cells through a block of autophagic flux dependent on PPARÎ³ down-regulation. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 1029-42.	4.9	41
305	Adipose tissue and liver metabolic responses to different levels of dietary carbohydrates in gilthead sea bream (Sparus aurata). Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2014, 175, 72-81.	1.8	39
306	Expression profile and role of prostacyclin receptor (PTGIR) in peri-implantation porcine conceptuses. Theriogenology, 2014, 82, 546-556.	2.1	13
307	Targeting inflammation in diabetes: Newer therapeutic options. World Journal of Diabetes, 2014, 5, 697.	3.5	144
308	Peroxisome proliferator-activated receptor Î³ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis. Molecular Medicine Reports, 2014, 10, 695-700.	2.4	35
309	Peroxisome proliferator-activated receptor Î³ ligands inhibit VEGF-mediated vasculogenic mimicry of prostate cancer through the AKT signaling pathway. Molecular Medicine Reports, 2014, 10, 276-282.	2.4	25
310	Inhibition of aldose reductase ameliorates diet-induced nonalcoholic steatohepatitis in mice via modulating the phosphorylation of hepatic peroxisome proliferator-activated receptor Î±. Molecular Medicine Reports, 2015, 11, 303-308.	2.4	10
311	Transgenic expression of omega-3 PUFA synthesis genes improves zebrafish survival during Vibrio vulnificus infection. Journal of Biomedical Science, 2015, 22, 103.	7.0	27
312	A phase II clinical trial to investigate the effect of pioglitazone on 18F-FDG uptake in malignant lesions. EJNMMI Research, 2015, 5, 50.	2.5	2
313	Polymorphisms in the PPARÎ³ gene and their association with metabolic syndrome in Uyghurs and Kazakhs from Xinjiang, China. Genetics and Molecular Research, 2015, 14, 6279-6288.	0.2	3

#	Article	IF	Citations
314	Omega-3 Fatty Acid Supplementation for 12 Weeks Increases Resting and Exercise Metabolic Rate in Healthy Community-Dwelling Older Females. PLoS ONE, 2015, 10, e0144828.	2.5	113
315	Fetal and Childhood Exposure to Phthalate Diesters and Cognitive Function in Children Up to 12 Years of Age: Taiwanese Maternal and Infant Cohort Study. PLoS ONE, 2015, 10, e0131910.	2.5	64
316	Interleukin-18 Increases TLR4 and Mannose Receptor Expression and Modulates Cytokine Production in Human Monocytes. Mediators of Inflammation, 2015, 2015, 1-9.	3.0	15
317	Sequence Variants of Peroxisome Proliferator-Activated Receptor-Gamma Gene and the Clinical Courses of Patients with End-Stage Renal Disease. Disease Markers, 2015, 2015, 1-7.	1.3	8
318	Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions. PPAR Research, 2015, 2015, 1-18.	2.4	77
319	Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease. World Journal of Gastroenterology, 2015, 21, 1099.	3.3	30
320	Synthesis, biological evaluation and molecular modeling studies of the PPARÎ²/Î´ antagonist CC618. European Journal of Medicinal Chemistry, 2015, 94, 229-236.	5.5	8
321	Peroxisome Proliferator-Activated Receptor Gamma Negatively Regulates the Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells Toward Myofibroblasts in Liver Fibrogenesis. Cellular Physiology and Biochemistry, 2015, 37, 2085-2100.	1.6	18
322	BioGPS: Navigating biological space to predict polypharmacology, off-targeting, and selectivity. Proteins: Structure, Function and Bioinformatics, 2015, 83, 517-532.	2.6	68
323	Regulation of lipid metabolism and peroxisome proliferator-activated receptors in rainbow trout adipose tissue by lipolytic and antilipolytic endocrine factors. Domestic Animal Endocrinology, 2015, 51, 86-95.	1.6	9
324	The PPARÎ³ agonist, rosiglitazone, attenuates airway inflammation and remodeling via heme oxygenase-1 in murine model of asthma. Acta Pharmacologica Sinica, 2015, 36, 171-178.	6.1	33
325	In vitro evaluation of dual agonists for PPARÎ³/Î² from the flower of Edgeworthia gardneri (wall.) Meisn. Journal of Ethnopharmacology, 2015, 162, 14-19.	4.1	21
326	The effect of PPAR-Î³ agonist on 18F-FDG PET imaging for differentiating tumors and inflammation lesions. Nuclear Medicine and Biology, 2015, 42, 85-91.	0.6	5
327	Magnolol ameliorates lipopolysaccharide-induced acute lung injury in rats through PPAR-Î³-dependent inhibition of NF-kB activation. International Immunopharmacology, 2015, 28, 270-278.	3.8	77
328	New nanocomposite-graphene pastes based stochastic microsensors. RSC Advances, 2015, 5, 66185-66191.	3.6	10
329	Alteration of cellular lipids and lipid metabolism markers in RTL-W1 cells exposed to model endocrine disrupters. Aquatic Toxicology, 2015, 165, 277-285.	4.0	17
330	Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor Î±/Î³. Journal of Structural Biology, 2015, 191, 332-340.	2.8	34
331	PPARÎ± agonists based on stilbene and its bioisosteres: biological evaluation and docking studies. MedChemComm, 2015, 6, 1513-1517.	3.4	13

#	Article	IF	Citations
332	Rosiglitazone ameliorates senescence-like phenotypes in a cellular photoaging model. Journal of Dermatological Science, 2015, 77, 173-181.	1.9	13
333	Review of the roles of conjugated linoleic acid in health and disease. Journal of Functional Foods, 2015, 15, 314-325.	3.4	185
334	Transcriptome analysis of hen preadipocytes treated with an adipogenic cocktail (DMIOA) with or without 20(S)-hydroxylcholesterol. BMC Genomics, 2015, 16, 91.	2.8	12
335	Abundance of ruminal bacteria, epithelial gene expression, and systemic biomarkers of metabolism and inflammation are altered during the peripartal period in dairy cows. Journal of Dairy Science, 2015, 98, 8940-8951.	3.4	71
336	Cinnamaldehyde Contributes to Insulin Sensitivity by Activating PPARÎ´, PPARÎ³, and RXR. The American Journal of Chinese Medicine, 2015, 43, 879-892.	3.8	30
337	Valproic acid protects against haemorrhagic shockâ€induced signalling changes via PPARÎ³ activation in an in vitro model. British Journal of Pharmacology, 2015, 172, 5306-5317.	5.4	9
338	A Novel Peroxisome Proliferator-activated Receptor (PPAR)Î³ Agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate Exerts Anti-Inflammatory Effects in Colitis. Journal of Biological Chemistry, 2015, 290, 25609-25619.	3.4	49
339	The ubiquitin ligase MuRF1 regulates PPARÎ± activity in the heart by enhancing nuclear export via monoubiquitination. Molecular and Cellular Endocrinology, 2015, 413, 36-48.	3.2	42
340	Molecular characterization, transcriptional activity and nutritional regulation of peroxisome proliferator activated receptor gamma in Nile tilapia (Oreochromis niloticus). General and Comparative Endocrinology, 2015, 223, 139-147.	1.8	25
341	Pioglitazone hydrochloride: chemopreventive potential and development of site-specific drug delivery systems. Drug Delivery, 2015, 22, 408-417.	5.7	3
342	Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. Oncotarget, 2016, 7, 46603-46614.	1.8	41
343	PPARÎ³in Bacterial Infections: A Friend or Foe?. PPAR Research, 2016, 2016, 1-7.	2.4	21
344	PPARÎ³as a Novel Therapeutic Target in Lung Cancer. PPAR Research, 2016, 2016, 1-7.	2.4	37
345	Identification of Haplotype Tag Single-Nucleotide Polymorphisms within the PPAR Family Genes and Their Clinical Relevance in Patients with Major Trauma. International Journal of Environmental Research and Public Health, 2016, 13, 374.	2.6	4
346	Macrophage Polarization: Implications on Metabolic Diseases and the Role of Exercise. Critical Reviews in Eukaryotic Gene Expression, 2016, 26, 115-132.	0.9	57
347	A Novel Partial <scp>PPARÎ±</scp>/Î³ Dual Agonist <scp>SN159</scp> Improves Insulin Sensitivity. Bulletin of the Korean Chemical Society, 2016, 37, 226-233.	1.9	3
348	Peroxisome Proliferatorâ€Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies. Chemical Biology and Drug Design, 2016, 88, 17-25.	3.2	34
349	Dietary Î±-linolenic acid supplementation alters skeletal muscle plasma membrane lipid composition, sarcolemmal FAT/CD36 abundance, and palmitate transport rates. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 311, R1234-R1242.	1.8	25

#	Article	IF	Citations
350	Vascular and Central Activation of Peroxisome Proliferator-Activated Receptor-Â Attenuates Angiotensin II-Induced Hypertension: Role of RGS-5. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 151-163.	2.5	16
351	Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARÎ±) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and inÂvitro effects of fenofibrate in GH3 cells. Molecular and Cellular Endocrinology, 2016, 426, 61-72.	3.2	2
352	PPARÎ³ regulates exocrine pancreas lipase. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1921-1928.	2.4	6
353	Long-chain polyunsaturated fatty acids regulation of PPARs, signaling: Relationship to tissue development and aging. Prostaglandins Leukotrienes and Essential Fatty Acids, 2016, 114, 28-34.	2.2	150
354	Inundation of asthma target research: Untangling asthma riddles. Pulmonary Pharmacology and Therapeutics, 2016, 41, 60-85.	2.6	6
355	Modulation of Systemic Metabolism by MMPâ€2: From MMPâ€2 Deficiency in Mice to MMPâ€2 Deficiency in Patients. , 2016, 6, 1935-1949.		37
356	Peroxisome proliferator activating receptor-Î³ and the podocyte. Nephrology Dialysis Transplantation, 2017, 32, gfw320.	0.7	21
357	Peroxisome proliferator-activated receptor alpha acts as a mediator of endoplasmic reticulum stress-induced hepatocyte apoptosis in acute liver failure. DMM Disease Models and Mechanisms, 2016, 9, 799-809.	2.4	19
358	Peroxisome proliferator-activated receptor gamma (PPARÎ³), a key regulatory gene of lipid metabolism in chicken. World's Poultry Science Journal, 2016, 72, 773-784.	3.0	11
359	Fatty acid metabolism in fish species as a biomarker for environmental monitoring. Environmental Pollution, 2016, 218, 297-312.	7.5	70
360	Ursolic acid prevents augmented peripheral inflammation and inflammatory hyperalgesia in high-fat diet-induced obese rats by restoring downregulated spinal PPARÎ±. Molecular Medicine Reports, 2016, 13, 5309-5316.	2.4	17
361	Effects of telmisartan on fat distribution: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 2016, 32, 1303-1309.	1.9	11
362	Inhibition of glycogen synthase kinase 3Î² promotes autophagy to protect mice from acute liver failure mediated by peroxisome proliferator-activated receptor Î±. Cell Death and Disease, 2016, 7, e2151-e2151.	6.3	62
363	Mechanisms underlying the effect of polysaccharides in the treatment of type 2 diabetes: A review. Carbohydrate Polymers, 2016, 144, 474-494.	10.2	185
364	Oral Supplementation with Cocoa Extract Reduces UVB-Induced Wrinkles in HairlessÂMouse Skin. Journal of Investigative Dermatology, 2016, 136, 1012-1021.	0.7	29
365	Macrophage-derived lipid agonists of PPAR-Î±as intrinsic controllers of inflammation. Critical Reviews in Biochemistry and Molecular Biology, 2016, 51, 7-14.	5.2	62
366	In SilicoModeling for the Prediction of Dose and Pathway-Related Adverse Effects in Humans FromIn VitroRepeated-Dose Studies. Toxicological Sciences, 2016, 149, 55-66.	3.1	14
367	Rosiglitazone protects rat liver against acute liver injury associated with the NF-ÎºB signaling pathway. Canadian Journal of Physiology and Pharmacology, 2016, 94, 28-34.	1.4	14

#	Article	IF	Citations
368	Pharmacological evidence for systemic and peripheral antinociceptive activities of pioglitazone in the rat formalin test: Role of PPARÎ³ and nitric oxide. European Journal of Pharmacology, 2017, 805, 84-92.	3.5	20
369	Cloning and expression characterization of peroxisome proliferator-activated receptors (PPARs) with their agonists, dietary lipids, and ambient salinity in rabbitfish Siganus canaliculatus. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2017, 206, 54-64.	1.6	27
370	Antihypertensive effects of peroxisome proliferator-activated receptor-Î²/Î´ activation. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 312, H189-H200.	3.2	26
371	Intellectual evaluation of children exposed to phthalate-tainted products after the 2011 Taiwan phthalate episode. Environmental Research, 2017, 156, 158-166.	7.5	38
373	Antarctic seals: Molecular biomarkers as indicators for pollutant exposure, health effects and diet. Science of the Total Environment, 2017, 599-600, 1693-1704.	8.0	12
374	Peroxisome proliferator-activated receptor alpha mediates C/EBP homologous protein to protect mice from acute liver failure. Inflammation Research, 2017, 66, 813-822.	4.0	3
375	Quantitative targeted metabolomics for 15d-deoxy-Î”12, 14-PGJ2 (15d-PGJ2) by MALDI-MS. Biotechnology and Bioprocess Engineering, 2017, 22, 100-106.	2.6	3
376	Traditional medicine, Sobokchukeo-Tang, modulates the inflammatory response in adipocytes and macrophages. Molecular Medicine Reports, 2017, 15, 117-124.	2.4	3
377	Gene expression modulation of lipid and central energetic metabolism related genes by high-fat diet intake in the main homeostatic tissues. Food and Function, 2017, 8, 629-650.	4.6	22
378	Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARÎ³ Agonists and their Antidiabetic Effects on Type 2 Diabetes. Scientific Reports, 2017, 7, 14453.	3.3	35
379	The PPARÎ± activator fenofibrate inhibits voltage-dependent K + channels in rabbit coronary arterial smooth muscle cells. European Journal of Pharmacology, 2017, 812, 155-162.	3.5	5
380	Wogonin attenuates inflammation by activating PPAR-Î³ in alcoholic liver disease. International Immunopharmacology, 2017, 50, 95-106.	3.8	51
381	Peroxisome proliferator-activated receptor (PPAR) isoforms are differentially expressed in peri-implantation porcine conceptuses. Theriogenology, 2017, 101, 53-61.	2.1	16
382	PPARÎ± Antagonist AA452 Triggers Metabolic Reprogramming and Increases Sensitivity to Radiation Therapy in Human Glioblastoma Primary Cells. Journal of Cellular Physiology, 2017, 232, 1458-1466.	4.1	26
383	Impact of Interaction Between PPAR Alpha and PPAR Gamma on Breast Cancer Risk in the Chinese Han Population. Clinical Breast Cancer, 2017, 17, 336-340.	2.4	12
384	Consumption of a high-fat, high-calorie meal is associated with an increase in intracellular co-localization of PPAR-Î³ mRNA and protein in monocytes. Methods, 2017, 112, 182-187.	3.8	8
385	PPAR-Î± Modulates the Anti-Inflammatory Effect of Melatonin in the Secondary Events of Spinal Cord Injury. Molecular Neurobiology, 2017, 54, 5973-5987.	4.0	31
386	Structures of PPARÎ³ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs. Scientific Reports, 2017, 7, 16837.	3.3	63

#	Article	IF	Citations
387	Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway. PPAR Research, 2017, 2017, 1-15.	2.4	119
388	PPAR Agonists for the Prevention and Treatment of Lung Cancer. PPAR Research, 2017, 2017, 1-8.	2.4	44
389	Inhibition of aldose reductase ameliorates ethanol-induced steatosis in HepG2 cells. Molecular Medicine Reports, 2017, 15, 2732-2736.	2.4	13
390	The influence of arachidonic acid metabolites on PPAR and RXR expression in bovine uterine cells. General and Comparative Endocrinology, 2018, 262, 27-35.	1.8	6
391	Orange juice affects acylcarnitine metabolism in healthy volunteers as revealed by a mass-spectrometry based metabolomics approach. Food Research International, 2018, 107, 346-352.	6.2	20
392	The effects of parental carbamazepine and gemfibrozil exposure on sexual differentiation in zebrafish (Danio rerio). Environmental Toxicology and Chemistry, 2018, 37, 1696-1706.	4.3	9
393	Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation. Hormone Molecular Biology and Clinical Investigation, 2018, 36, .	0.7	40
394	Molecular association model of PPARÎ± and its new specific and efficient ligand, pemafibrate: Structural basis for SPPARMÎ±. Biochemical and Biophysical Research Communications, 2018, 499, 239-245.	2.1	47
395	The role of various peroxisome proliferatorâ€activated receptors and their ligands in clinical practice. Journal of Cellular Physiology, 2018, 233, 153-161.	4.1	134
396	Anti-hypertensive and cardioprotective effects of a novel apitherapy formulation via upregulation of peroxisome proliferator-activated receptor-Î± and -Î³ in spontaneous hypertensive rats. Saudi Journal of Biological Sciences, 2018, 25, 213-219.	3.8	13
397	Clinical relevance of peroxisome proliferatorâ€activated receptorâ€Î³ gene polymorphisms with sepsis. Journal of Clinical Laboratory Analysis, 2018, 32, e22340.	2.1	2
398	Oral administration of a novel lipophilic PPARÎ´ agonist is not neuroprotective after rodent cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 174-185.	4.3	2
399	Polygonatum odoratum Polysaccharides Modulate Gut Microbiota and Mitigate Experimentally Induced Obesity in Rats. International Journal of Molecular Sciences, 2018, 19, 3587.	4.1	83
400	Targeting PPARÎ± for the Treatment and Understanding of Cardiovascular Diseases. Cellular Physiology and Biochemistry, 2018, 51, 2760-2775.	1.6	36
401	The Transcriptional Factor PPARÎ±b Positively Regulates Elovl5 Elongase in Golden Pompano Trachinotus ovatus (Linnaeus 1758). Frontiers in Physiology, 2018, 9, 1340.	2.8	14
402	Chrysin attenuates interstitial fibrosis and improves cardiac function in a rat model of acute myocardial infarction. Journal of Molecular Histology, 2018, 49, 555-565.	2.2	38
403	Peroxisome proliferator-activated receptor-Î³ and its related pathway in bone marrow mesenchymal stem cell differentiation co-cultured with mechanically stretched ligament fibroblasts. International Journal of Molecular Medicine, 2018, 42, 219-227.	4.0	5
404	Lipid profile of bovine blastocysts exposed to insulin during in vitro oocyte maturation. Reproduction, Fertility and Development, 2018, 30, 1253.	0.4	4

#	Article	IF	Citations
405	Chapter 1 Antioxidant systems in animal body. , 2018, , 19-65.		0
406	Parental high dietary arachidonic acid levels modulated the hepatic transcriptome of adult zebrafish (Danio rerio) progeny. PLoS ONE, 2018, 13, e0201278.	2.5	14
407	Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis. International Journal of Molecular Sciences, 2018, 19, 949.	4.1	99
408	Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARÎ±) in Non-Somatotroph Pituitary Tumours and the Effects of PPARÎ± Agonists on MMQ Cells. Hormone and Metabolic Research, 2018, 50, 640-647.	1.5	3
409	Dietary Î±â€cyclodextrin modifies gut microbiota and reduces fat accumulation in highâ€fatâ€dietâ€fed obese mice. BioFactors, 2018, 44, 336-347.	5.4	44
410	Haem oxygenaseâ€1 upâ€regulation by rosiglitazone via ROSâ€dependent Nrf2â€antioxidant response elements axis or PPARÎ³ attenuates LPSâ€mediated lung inflammation. British Journal of Pharmacology, 2018, 175, 3928-3946.	5.4	48
411	Impact of lipid modulation on the intestinal microcirculation in experimental sepsis. Microvascular Research, 2018, 120, 41-46.	2.5	4
412	Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study. MedChemComm, 2019, 10, 1892-1899.	3.4	3
413	The effect of resveratrol supplementation on the expression levels of factors associated with cellular senescence and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: study protocol for a double-blind controlled randomised clinical trial. BMJ Open, 2019, 9, e026337.	1.9	7
414	Natural compounds in the chemoprevention of alcoholic liver disease. Phytotherapy Research, 2019, 33, 2192-2212.	5.8	24
415	Evaluation of the Anti-Diabetic Activity of Some Common Herbs and Spices: Providing New Insights with Inverse Virtual Screening. Molecules, 2019, 24, 4030.	3.8	60
416	Immunometabolism of Phagocytes During Mycobacterium tuberculosis Infection. Frontiers in Molecular Biosciences, 2019, 6, 105.	3.5	65
417	Effects of dietary glutamine supplementation on growth performance, antioxidant status and intestinal function in juvenile grass carp (Ctenopharyngodon idella). Aquaculture Nutrition, 2019, 25, 609-621.	2.7	17
418	Regulation of expression and role of peroxisome proliferator-activated receptors (PPARs) in luminal epithelial and stromal cells of the porcine endometrium. Theriogenology, 2019, 127, 88-101.	2.1	14
419	Identification and characterization of a novel anti-inflammatory lipid isolated from Mycobacterium vaccae, a soil-derived bacterium with immunoregulatory and stress resilience properties. Psychopharmacology, 2019, 236, 1653-1670.	3.1	28
420	Bronchopulmonary Dysplasia: Crosstalk Between PPARÎ³, WNT/Î²-Catenin and TGF-Î² Pathways; The Potential Therapeutic Role of PPARÎ³ Agonists. Frontiers in Pediatrics, 2019, 7, 176.	1.9	29
421	Metabolic reprogramming in atherosclerosis: Opposed interplay between the canonical WNT/Î²-catenin pathway and PPARÎ³. Journal of Molecular and Cellular Cardiology, 2019, 133, 36-46.	1.9	29
422	Do arachidonic acid metabolites affect apoptosis in bovine endometrial cells with silenced PPAR genes?. Prostaglandins and Other Lipid Mediators, 2019, 143, 106336.	1.9	4

#	Article	IF	Citations
423	An update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligands. European Journal of Medicinal Chemistry, 2019, 176, 326-342.	5.5	3
424	Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-Î±/VLCAD pathway. Lipids in Health and Disease, 2019, 18, 109.	3.0	45
425	The association between prenatal exposure to phthalates and cognition and neurobehavior of children-evidence from birth cohorts. NeuroToxicology, 2019, 73, 199-212.	3.0	75
426	Elovl4a participates in LC-PUFA biosynthesis and is regulated by PPARÎ±Î² in golden pompano Trachinotus ovatus (Linnaeus 1758). Scientific Reports, 2019, 9, 4684.	3.3	27
427	Bioâ€derived hydroxystearic acid ameliorates skin age spots and conspicuous pores. International Journal of Cosmetic Science, 2019, 41, 240-256.	2.6	17
428	Novel Phenyldiazenyl Fibrate Analogues as PPAR Î±/Î³/Î´ Pan-Agonists for the Amelioration of Metabolic Syndrome. ACS Medicinal Chemistry Letters, 2019, 10, 545-551.	2.8	21
429	Effects of gemfibrozil on sex hormones and reproduction related performances of Oryzias latipes following long-term (155 d) and short-term (21 d) exposure. Ecotoxicology and Environmental Safety, 2019, 173, 174-181.	6.0	9
430	Mapping Research in the Obesity, Adipose Tissue, and MicroRNA Field: A Bibliometric Analysis. Cells, 2019, 8, 1581.	4.1	16
431	Identification of Fatty Acid Desaturase 6 in Golden Pompano Trachinotus Ovatus (Linnaeus 1758) and Its Regulation by the PPARÎ±b Transcription Factor. International Journal of Molecular Sciences, 2019, 20, 23.	4.1	42
432	Citrate reduced oxidative damage in stem cells by regulating cellular redox signaling pathways and represent a potential treatment for oxidative stress-induced diseases. Redox Biology, 2019, 21, 101057.	9.0	25
433	Hydroxytyrosol supplementation ameliorates the metabolic disturbances in white adipose tissue from mice fed a high-fat diet through recovery of transcription factors Nrf2, SREBP-1c, PPAR-Î³ and NF-ÎºB. Biomedicine and Pharmacotherapy, 2019, 109, 2472-2481.	5.6	106
434	Expression and role of peroxisome proliferatorâ€“activated receptors in the porcine early placenta trophoblast. Domestic Animal Endocrinology, 2019, 67, 42-53.	1.6	9
435	Osteoblastic differentiation improved by bezafibrate-induced mitochondrial biogenesis in deciduous tooth-derived pulp stem cells from a child with Leigh syndrome. Biochemistry and Biophysics Reports, 2019, 17, 32-37.	1.3	5
436	Peroxisome proliferatorâ€activated receptor alpha regulates the expression of the immune response mediators in the porcine endometrium during the estrous cycle and early pregnancy. American Journal of Reproductive Immunology, 2020, 83, e13211.	1.2	2
437	Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells, 2020, 9, 37.	4.1	85
438	Cell-Based Mechanosensation, Epigenetics, and Non-Coding RNAs in Progression of Cardiac Fibrosis. International Journal of Molecular Sciences, 2020, 21, 28.	4.1	20
439	Therapeutic Potential of Î²-Caryophyllene: A Dietary Cannabinoid in Diabetes and Associated Complications. Nutrients, 2020, 12, 2963.	4.1	34
440	PPAR-Î´ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-Î³. Regenerative Therapy, 2020, 15, 103-111.	3.0	7

#	Article	IF	Citations
441	DIA-DB: A Database and Web Server for the Prediction of Diabetes Drugs. Journal of Chemical Information and Modeling, 2020, 60, 4124-4130.	5.4	12
442	Dietary and plasma blood Î±-linolenic acid as modulators of fat oxidation and predictors of aerobic performance. Journal of the International Society of Sports Nutrition, 2020, 17, 57.	3.9	7
443	Peroxisome proliferator-activated receptor gamma expression along the male genital system and its role in male fertility. Human Reproduction, 2020, 35, 2072-2085.	0.9	14
444	Lipid metabolic features of skeletal muscle in pathological and physiological conditions. , 2020, , 359-383.		4
445	Transcription factor pparÎ±b activates fads2s to promote LC-PUFA biosynthesis in the golden pompano Trachinotus ovatus (Linnaeus 1758). International Journal of Biological Macromolecules, 2020, 161, 605-616.	7.5	5
446	Peroxisome proliferator-activated receptor Î²/Î´ and Î³ agonists differentially affect prostaglandin E2 and cytokine synthesis and nutrient transporter expression in porcine trophoblast cells during implantation. Theriogenology, 2020, 152, 36-46.	2.1	6
447	A natural supplement formula reduces anti-oxidative stress and enhances osteo-chondrogenic differentiation potential in mesenchymal stem cells. Journal of Clinical Biochemistry and Nutrition, 2020, 66, 206-212.	1.4	6
448	Resveratrol Alleviates Endoplasmic Reticulum Stressâ€“Associated Hepatic Steatosis and Injury in Mice Challenged with Tunicamycin. Molecular Nutrition and Food Research, 2020, 64, e2000105.	3.3	19
449	Induction of peroxisome proliferator activated receptor Î³ (PPARÎ³) mediated gene expression and inhibition of induced nitric oxide production by Maerua subcordata (Gilg) DeWolf. BMC Complementary Medicine and Therapies, 2020, 20, 80.	2.7	8
451	Cytoplasmic PPARÎ³ is a marker of poor prognosis in patients with Cox-1 negative primary breast cancers. Journal of Translational Medicine, 2020, 18, 94.	4.4	19
452	Toxicogenomics provides insights to toxicity pathways of neonicotinoids to aquatic insect, Chironomus dilutus. Environmental Pollution, 2020, 260, 114011.	7.5	34
453	Keratinocyte aquaporinâ€3 expression induced by histone deacetylase inhibitors is mediated in part by peroxisome proliferatorâ€activated receptors (PPARs). Experimental Dermatology, 2020, 29, 380-386.	2.9	12
454	An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes. Journal of Advanced Research, 2020, 23, 163-205.	9.5	56
455	Transcriptomic analysis reveals common pathways and biomarkers associated with oxidative damage caused by mitochondrial toxicants in Chironomus dilutus. Chemosphere, 2020, 254, 126746.	8.2	2
456	Lead acetate induces apoptosis in Leydig cells by activating PPARÎ³/caspase-3/PARP pathway. International Journal of Environmental Health Research, 2021, 31, 34-44.	2.7	28
457	The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism: Clinical and Experimental, 2021, 114, 154338.	3.4	229
458	The main bioactive compounds of Scutellaria baicalensis Georgi. for alleviation of inflammatory cytokines: A comprehensive review. Biomedicine and Pharmacotherapy, 2021, 133, 110917.	5.6	121
459	Elucidating the Efficacy of Clinical Drugs Using FMO. , 2021, , 323-339.		0

#	Article	IF	Citations
460	A Review of Recent Studies on Bisphenol A and Phthalate Exposures and Child Neurodevelopment. International Journal of Environmental Research and Public Health, 2021, 18, 3585.	2.6	42
461	Posttranslational modifications as therapeutic targets for intestinal disorders. Pharmacological Research, 2021, 165, 105412.	7.1	11
462	Physical activity during pregnancy alters gene expression in neonatal tissue. Physiology International, 2021, , .	1.6	0
463	Peroxisome proliferator-activated receptor-Î³ as a novel and promising target for treating cancer via regulation of inflammation: A brief review. Mini-Reviews in Medicinal Chemistry, 2021, 21, .	2.4	2
464	Interplay of Opposing Effects of the WNT/Î²-Catenin Pathway and PPARÎ³ and Implications for SARS-CoV2 Treatment. Frontiers in Immunology, 2021, 12, 666693.	4.8	33
465	Paternal transâ€fatty acid and vitamin E diet affects rat offspring's semen quality and PPAR s expression. Andrologia, 2021, 53, e14082.	2.1	1
466	PPARÎ³ Agonists: Emergent Therapy in Endometriosis. Pharmaceuticals, 2021, 14, 543.	3.8	7
467	Zerumbone Ameliorates Neuropathic Pain Symptoms via Cannabinoid and PPAR Receptors Using In Vivo and In Silico Models. Molecules, 2021, 26, 3849.	3.8	11
468	How cytosolic compartments play safeguard functions against neuroinflammation and cell death in cerebral ischemia. Metabolic Brain Disease, 2021, 36, 1445-1467.	2.9	1
469	Integrated metabolomics analysis of the effect of PPARÎ´ agonist GW501516 on catabolism of BCAAs and carboxylic acids in diabetic mice. Chinese Chemical Letters, 2021, 32, 2197-2202.	9.0	10
470	Erythromycin inhibits cigarette smoke-induced inflammation through regulating the PPARÎ³/NF-Î°B signaling pathway in macrophages. International Immunopharmacology, 2021, 96, 107775.	3.8	6
471	The role of A268V exon-7 polymorphism of PPARA in development of axial spondyloarthritis. Turkish Journal of Biochemistry, 2021, .	0.5	0
472	Type 2 Diabetic Sepsis Patients Have a Lower Mortality Rate in Pioglitazone Use: A Nationwide 15-Year Propensity Score Matching Observational Study in Taiwan. Emergency Medicine International, 2021, 2021, 1-9.	0.8	1
473	Bioactive Lipid Mediators in the Initiation and Resolution of Inflammation after Spinal Cord Injury. Neuroscience, 2021, 466, 273-297.	2.3	24
474	Hypothyroidism Affects Uterine Function via the Modulation of Prostaglandin Signaling. Animals, 2021, 11, 2636.	2.3	5
475	A study to explore the effects of low dietary protein levels on the growth performance and nutritional metabolism of grass carp (Ctenopharyngodon idella) fry. Aquaculture, 2022, 546, 737324.	3.5	13
476	Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Trophoblast Functions. International Journal of Molecular Sciences, 2021, 22, 433.	4.1	22
477	Nuclear Receptor-Mediated Regulation of Phase II Conjugating Enzymes. , 0, , 61-110.		3

#	Article	IF	Citations
478	The Use of Metabolomics in Cancer Research. , 2010, , 141-166.		13
479	Docosahexaenoic Acid Containing Phosphatidylcholine Alleviates Obesity-Related Disorders in Obese Rats. , 2011, , 205-212.		2
480	SUMOylation in atherosclerosis. Clinica Chimica Acta, 2020, 508, 228-233.	1.1	9
481	Crosstalk between the canonical NF-Î²B and Notch signaling pathways inhibits PparÎ³ expression and promotes pancreatic cancer progression in mice. Journal of Clinical Investigation, 2011, 121, 4685-4699.	8.2	213
482	Polyunsaturated fatty acids and DNA methylation in colorectal cancer. World Journal of Clinical Cases, 2019, 7, 4172-4185.	0.8	14
483	Carnitine Enigma: From Antioxidant Action to Vitagene Regulation. Part 2. Transcription Factors and Practical Applications. Journal of Veterinary Science & Medicine, 2015, 3, .	0.1	15
484	Knockdown of PPAR Î´ Gene Promotes the Growth of Colon Cancer and Reduces the Sensitivity to Bevacizumab in Nude Mice Model. PLoS ONE, 2013, 8, e60715.	2.5	32
485	Inhibition of Oxygen-Induced Ischemic Retinal Neovascularization with Adenoviral 15-Lipoxygenase-1 Gene Transfer via Up-Regulation of PPAR-Î³ and Down-Regulation of VEGFR-2 Expression. PLoS ONE, 2014, 9, e85824.	2.5	14
486	Comparative Design, In Silico Dockingand Predictive ADME/ TOX Properties of Some Novel 2, 4-hydroxy Derivatives of Thiazolidine-2, 4-diones as PPARÃŽÂ³ Modulator. Journal of Pharmaceutical Chemistry, 2017, 4, 11-19.	0.2	3
487	PPAR Ligands Containing Stilbene Scaffold. Mini-Reviews in Medicinal Chemistry, 2019, 19, 1599-1610.	2.4	6
488	Novel Cinnamic Acid Derivatives as Potential PPARÎ´ Agonists for Metabolic Syndrome: Design, Synthesis, Evaluation and Docking Studies. Current Drug Discovery Technologies, 2020, 17, 338-347.	1.2	3
489	Effects of Glycyrrhetic Acid (GE) on Some Gluconeogenic Enzymes, Lipoprotein Lipase and Peroxisome Proliferator-Activated Receptors Alpha and Gamma. The Open Bioactive Compounds Journal, 2013, 4, 14-24.	0.8	4
490	Peroxisome proliferator-activated receptor gamma as modulator of inflammation in pulmonary sarcoidosis. Srpski Arhiv Za Celokupno Lekarstvo, 2013, 141, 705-709.	0.2	6
491	Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (Â/Â) Peroxisome Proliferator-Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care, 2006, 29, 1016-1023.	8.6	64
492	Pioglitazone Attenuates Allergic Inflammation and Induces Production of Regulatory T Lymphocytes. American Journal of Rhinology and Allergy, 2010, 24, 454-458.	2.0	8
493	Rhodanine as a Scaffold: A Short Review on Its Synthesis and Anti-Diabetic Activities. Heterocycles, 2018, 96, 803.	0.7	4
494	The role of peroxisome proliferator-activated receptors in human disease. Indian Journal of Pharmacology, 2006, 38, 243.	0.7	13
495	Exploring the Role of Fatty Acid on Transcription Factors Regulating Fatty Acid Metabolism with Emphasis on Trans Fatty Acid. Food and Nutrition Sciences (Print), 2013, 04, 33-38.	0.4	2

#	Article	IF	Citations
496	Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Medical Weekly, 2010, 140, w13071.	1.6	113
497	Effect of Pioglitazone on Body Composition in Asian Indian Diabetics Suggest Role of Limb Fat in their High Insulin Resistance. British Journal of Medicine and Medical Research, 2016, 11, 1-11.	0.2	1
498	Knockdown of PPARÎ´ Induces VEGFA-Mediated Angiogenesis via Interaction With ERO1A in Human Colorectal Cancer. Frontiers in Oncology, 2021, 11, 713892.	2.8	3
499	Cheonggukjang-Specific Component 1,3-Diphenyl-2-Propanone as a Novel PPARÎ±/Î³ Dual Agonist: An In Vitro and In Silico Study. International Journal of Molecular Sciences, 2021, 22, 10884.	4.1	1
500	The Role of TGF-Î² in Radiation and Chemotherapy Induced Pulmonary Fibrosis: Inhibition of TGF-Î² as a Novel Therapeutic Strategy. , 2008, , 629-647.		0
501	Biochemie der ErnÃhrung. , 2010, , 3-21.		0
502	Modulation of glucose and lipid metabolism in adrenalectomised rats given glycyrrhizic acid. Journal of Molecular Pathophysiology, 2012, 1, 3.	0.3	2
503	Effect of PPAR-Î² Gene on Human Colon Cancer Growth in Vivo and Molecular Mechanism. World Journal of Cancer Research, 2013, 03, 24-32.	0.1	0
504	Macrophage Polarization in Infectious Diseases. Journal of Clinical & Cellular Immunology, 2015, 06, .	1.5	0
505	Influence of Peroxisome Proliferator-Activated Receptors (PPARs) and Liver X Receptors (LXRs) on Development of Artherosclerosis. , 2015, , 1-32.		0
506	Influence of Peroxisome Proliferator-Activated Receptors (PPARs) and Liver X Receptors (LXRs) on Development of Artherosclerosis. , 2016, , 2295-2322.		0
507	Evaluation of Effect of Nishamalaki on STZ and HFHF Diet Induced Diabetic Neuropathy in Wistar Rats. Journal of Clinical and Diagnostic Research JCDR, 2016, 10, FF01-FF05.	0.8	7
508	Open clinical study of antihypertensive efficacy of generic drug telmisartan (hypotel) or a combination with S-amlodipine (Semlopin) or hydrochlorothiazide in the therapy of patients with		

#	Article	IF	Citations
515	Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. Iranian Journal of Pharmaceutical Research, 2011, 10, 655-83.	0.5	234
516	The Role of Immunogenicity in Cardiovascular Disease. World Heart Journal, 2011, 3, 1-29.	0.0	11
518	Modulation of lipid metabolism in glycyrrhizic acid-treated rats fed on a high-calorie diet and exposed to short or long-term stress. International Journal of Physiology, Pathophysiology and Pharmacology, 2015, 7, 61-75.	0.8	5
519	Peroxisome proliferator-activated receptors (PPARÎ±, PPARÎ³ and PPARÎ²/Î´) gene expression profile on ram spermatozoa and their relation to the sperm motility. Veterinary Research Forum, 2016, 7, 27-34.	0.3	14
520	Effect of elaidic acid on ABCA1 expression in raw 264.7 cells. Is it through PPAR-gamma?. EXCLI Journal, 2018, 17, 864-870.	0.7	0
521	Abscisic acid interplays with PPARÎ³ receptors and ameliorates diabetes-induced cognitive deficits in rats. Avicenna Journal of Phytomedicine, 2021, 11, 247-257.	0.2	1
522	Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Energy Homeostasis of Dairy Animals: Exploiting Their Modulation through Nutrigenomic Interventions. International Journal of Molecular Sciences, 2021, 22, 12463.	4.1	16
523	Rapidly Growing Mycobacterium Species: The Long and Winding Road from Tuberculosis Vaccines to Potent Stress-Resilience Agents. International Journal of Molecular Sciences, 2021, 22, 12938.	4.1	9
524	In vitro and in vivo antidiabetic activity, isolation of flavonoids, and in silico molecular docking of stem extract of Merremia tridentata (L.). Biomedicine and Pharmacotherapy, 2022, 146, 112611.	5.6	21
525	Costly immunometabolic remodelling in disused muscle buildup through physical exercise. Acta Physiologica, 2022, 234, e13782.	3.8	5
526	The initial expression alterations occurring to transcription factors during the formation of breast cancer: Evidence from bioinformatics. Cancer Medicine, 2022, 11, 1371-1395.	2.8	6
527	<i>In Vitro</i> and <i>In Vivo</i> Antidiabetic Activity, Isolation of Flavonoids, and <i>In Silico</i> Molecular Docking of Stem Extract of <i>Merremia tridentata</i> (L.). SSRN Electronic Journal, 0, , .	0.4	0
528	Exploring the Pattern of Metabolic Alterations Causing Energy Imbalance via PPARÎ± Dysregulation in Cardiac Muscle During Doxorubicin Treatment. Cardiovascular Toxicology, 2022, 22, 436-461.	2.7	7
529	Neuroinflammation in Schizophrenia: The Key Role of the WNT/Î²-Catenin Pathway. International Journal of Molecular Sciences, 2022, 23, 2810.	4.1	40
530	Molecular characterization, expression and functional analysis of large yellow croaker (Larimichthys crocea) peroxisome proliferator-activated receptor gamma. Fish and Shellfish Immunology, 2022, 123, 50-60.	3.6	1
531	A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity. European Journal of Medicinal Chemistry, 2022, 235, 114240.	5.5	5
549	Beyond PXR and CAR, Regulation of Xenobiotic Metabolism by other Nuclear Receptors. , 0, , 275-300.		0
550	Peroxisome proliferator-activated receptor delta-PPARÎ´ agonist (L-165041) enhances bovine embryo survival and post vitrification viability. Reproduction, Fertility and Development, 2022, , .	0.4	0

#	Article	IF	Citations
552	PPARÎ± Signaling: A Candidate Target in Psychiatric Disorder Management. Biomolecules, 2022, 12, 723.	4.0	7
553	Effects of Amino Acids Supplementation on Lipid and Glucose Metabolism in HepG2 Cells. Nutrients, 2022, 14, 3050.	4.1	6
554	The Small Molecule PPARÎ³ Agonist GL516 Induces Feeding-Stimulatory Effects in Hypothalamus Cells Hypo-E22 and Isolated Hypothalami. Molecules, 2022, 27, 4882.	3.8	1
555	Dietary Protein Modifies Hepatic Glycolipid Metabolism, Intestinal Immune Response, and Resistance to Streptococcus agalactiae of Genetically Improved Farmed Tilapia (GIFT: Oreochromis niloticus) Exposed to High Temperature. Fishes, 2022, 7, 202.	1.7	2
556	Evaluation of the expression pattern and diagnostic value of PPARÎ³ in malignant and benign primary bone tumors. BMC Musculoskeletal Disorders, 2022, 23, .	1.9	6
557	New 4-thiazolidinone-based molecules Les-2769 and Les-3266 as possible PPARÎ³ modulators. Bioorganic Chemistry, 2022, 128, 106075.	4.1	6
558	Natural Product Ligands of the Peroxisome Proliferator-Activated Receptor Gamma as Anti-Inflammatory Mediators. Natural Products Journal, 2023, 13, .	0.3	1
559	Activation of PPARÎ³ Protects Obese Mice from Acute Lung Injury by Inhibiting Endoplasmic Reticulum Stress and Promoting Mitochondrial Biogenesis. PPAR Research, 2022, 2022, 1-15.	2.4	4
560	Auraptene, a citrus peel-derived natural product, prevents myocardial infarction-induced heart failure by activating PPARÎ± in rats. Phytomedicine, 2022, 107, 154457.	5.3	6
561	Thiazolidin-2,4-Dione Scaffold: An Insight into Recent Advances as Antimicrobial, Antioxidant, and Hypoglycemic Agents. Molecules, 2022, 27, 6763.	3.8	14
562	Mouse models of nonalcoholic steatohepatitis and their application to new drug development. Archives of Pharmacal Research, 2022, 45, 761-794.	6.3	5
563	Evaluation of the Relationship between Peroxisome Proliferator Receptors (PPARÎ±, PPARÎ³, and PPARÎ´) Expression and Carcinoembryonic Antigen (CEA) in Patients with Colorectal Cancer. Majallah-i DÄ•nishgÄ•h-i â€™UlÅ«m-i PizishkÄ«-i Ä³lÄ•m, 2022, 30, 75-87.	0.0	0
564	Pu'er raw tea extract alleviates lipid deposition in both LO2 cells and Caenorhabditis elegans. Food Bioscience, 2022, 50, 102172.	4.4	4
565	Potential for Omega-3 Fatty Acids to Protect against the Adverse Effect of Phytosterols: Comparing Laboratory Outcomes in Adult Patients on Home Parenteral Nutrition Including Different Lipid Emulsions. Biology, 2022, 11, 1699.	2.8	1
567	Emerging Role of SMILE in Liver Metabolism. International Journal of Molecular Sciences, 2023, 24, 2907.	4.1	0
568	The role of peroxisome proliferator-activated receptors in the modulation of hyperinflammation induced by SARS-CoV-2 infection: A perspective for COVID-19 therapy. Frontiers in Immunology, 0, 14, .	4.8	7
569	Rosiglitazone-induced PPARÎ³ activation promotes intramuscular adipocyte adipogenesis of pig. Animal Biotechnology, 0, , 1-10.	1.5	1
570	Design, synthesis and anti-NASH effect evaluation of novel GFT505 derivatives in vitro and in vivo. European Journal of Medicinal Chemistry, 2023, 257, 115510.	5.5	2

#	Article	IF	Citations
571	Novel 1,2,4-oxadiazole compounds as PPAR-Î± ligand agonists: a new strategy for the design of antitumour compounds. RSC Medicinal Chemistry, 0, , .	3.9	0
572	The role of peroxisome proliferator-activated receptors in the tumor microenvironment, tumor cell metabolism, and anticancer therapy. Frontiers in Pharmacology, 0, 14, .	3.5	4
573	The role of PPAR-Î³ in memory deficits induced by prenatal and lactation alcohol exposure in mice. Molecular Psychiatry, 0, , .	7.9	0
574	Identification of the novel markers of <scp>PPAR</scp> signalling affecting immune microenvironment and immunotherapy response of lung adenocarcinoma patients. Journal of Cellular and Molecular Medicine, 2024, 28, .	3.6	0
575	Potential therapeutic targets of macrophages in inhibiting immune damage and fibrotic processes in musculoskeletal diseases. Frontiers in Immunology, 0, 14, .	4.8	2
576	Neuroinflammation in the Central Nervous System: Exploring the Evolving Influence of Endocannabinoid System. Biomedicines, 2023, 11, 2642.	3.2	2
577	Molecular Docking Studies of Novel Thiazolidinedionederivatives as PPARÎ³ Modulators. Journal of Pharmaceutical Chemistry, 0, 9, 12-21.	0.2	0
578	Advances in polysaccharides of natural source of anti-diabetes effect and mechanism. Molecular Biology Reports, 2024, 51, .	2.3	1
579	pparÎ² regulates lipid catabolism by mediating acox and cpt-1 genes in Scophthalmus maximus under heat stress. Fish Physiology and Biochemistry, 2024, 50, 295-305.	2.3	0
580	Tissue fibrosis associated depletion of lipidâ€filled cells. Experimental Dermatology, 2024, 33, .	2.9	0